- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
|
|
| 52wk high: | |
| 52wk low: | |
| EPS: | |
| PE: | |
| Dividend: | |
| Yield: | |
| Market Cap: | |
| Exchange: | |
Articles on Roche Holdings AG Basel (RHHBY.PK)
by latest | most commented
-
Curagen: Positive Results at ASCO 2009
-
Dealmaking Sweeps the Biotech Sector
-
European Dividend Trends
-
Pharmaceutical Dollar Rationing by Results
-
A Healthy Dose of Funding for Pharma, Biotech
-
Redefining Pharma as Biotech Dominates Industry's Growth
-
Biotech Set to Dominate Drug Industry Growth
-
Companies Involved in the Treatment of Swine Flu
-
Alimta: The 'Winner' of ASCO 2009
-
Astra Zeneca Short Base Still High, But Declining
-
Keryx: Another Beneficiary of the ASCO Effect
-
FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO
-
Bio-Rad Sparks Video War Among Lab Supply Companies
-
China Biotech in Review: Deals, Approvals and More
-
Roche Launches China Biopharma Application Support Center
-
Access Pharma: A Smallcap Cancer Biotech Call Option Trade
-
Top Biotech Picks for ASCO 2009 (Part II)
-
FDA, Clinical Trial Updates: Biogen, Roche, Salix, Cell Therapeutics, Pfizer
-
Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches
-
Downturn Has Transformed Drug Company Business Model
-
Roche and Genentech: Get Your Act Together
-
FDA Calendar Updates: Acorda, Roche
-
Swine Flu: A Follow-Up on 'Trading the Hype'
-
Swine Flu: Trade Smartly, Beware the Hype
-
Swine Flu Stock Watchlist
-
Mexican Flu Pandemic: Potential Trade Opportunity
-
Personalized Medicine: The Next Big Thing
-
Anti-Virals: Swine Flu's Impact on Sales
-
The Swine Flu Effect
-
Swine Flu: Current Status and Worst Case Scenario
-
Short Term Swine Flu Trades
-
This Week's 20 'Babies with Bath Water' and 16 'Dogs with Fleas'
-
Possible Swine Flu Profit Trades
-
Three Companies That Could Benefit from Swine Flu
-
Rare Failure for Roche's Avastin
-
FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson
-
Wall Street Breakfast: Must-Know News
-
Preview from Europe: Geithner's Soothing Words Send Stocks Higher
-
Wall Street Breakfast: Must-Know News
-
Is Roche Already Transforming Genentech's 'Culture'?
-
Opportunities in Healthcare: Highly Defensive Stocks